Stage 4 Ovarian Cancer Survival Rate by Age

Stage 4 ovarian cancer, where the cancer has spread beyond the abdomen, has one of the lowest survival rates of any stage at any age: roughly 1 in 6 women live five years. Age still shifts the outlook a great deal. Younger women live markedly longer than women in their 80s, whose five-year rate is about 3%. Part of that gap comes from older women receiving less treatment, not only from age itself.

Survival Rates for Stage 4 Ovarian Cancer at Different Ages

All ages: about 16% of women with stage 4 ovarian cancer lived 5 years in recent periods.¹
Under 80 versus 80 and older: about 13% of women under 80 with stage 4 disease lived 5 years, compared with about 3% at 80 and older.²
Stages 3 and 4 together: women under 45 had a 5-year survival over 45%, compared with 8% at 85 and older.³
First year, stages 3 and 4: about 76% of women aged 20-49 were alive relative to the general population, versus 34% of the oldest women.⁴
Oldest women, widely spread disease: 3-year survival ranged from 12% to 24% depending on the country.⁵

Many studies group stages 3 and 4, so pure stage 4 numbers by age are scarce. Combined figures look better than stage 4 alone, because stage 3 does somewhat better. Treat any stage 3-4 figure as an upper bound for stage 4.

Many of these figures are “relative survival,” meaning survival compared with women the same age who don’t have cancer. Normal deaths from old age are already factored out, so the drop in older women reflects the cancer and its treatment.

The gap between women under 45 and women 80 and older is real, but those groups differ in more than their birth year. Younger women are more often fit enough for full surgery and chemotherapy, so part of their advantage comes from the treatment they receive. The numbers describe an average for each age group, not a limit on any one woman.

Stage 4 survival also improved over time, from about 11% to 16% at 5 years within a decade.⁶ Published rates describe women diagnosed years ago, so they likely understate today’s outlook.

A 5-year rate is a snapshot of a group of women diagnosed years ago. It counts only who is alive at the 5-year mark, so it says nothing about whether the others lived one year or four. Some women in every age group live well beyond the average. To get a figure that fits your situation, ask the oncologist how your age, general fitness and tumor type change the picture.

Why Older Women Have Lower Survival

Undertreatment drives much of the gap. In a nationwide study of advanced ovarian cancer, 52% of older women had no tumor-removing surgery, versus 25% of younger women.⁷ Older women who did have surgery had less extensive operations and more often had cancer left behind. They were also less often given chemotherapy.⁸

Families often hear that surgery is too risky at an older age. That can be a fair judgment when a woman is frail or has serious heart or lung disease. But birth year alone is a poor guide to who can handle treatment. A healthy 78-year-old may tolerate an operation better than a younger woman with other serious illnesses. When surgery is skipped, more tumor remains, and that can shorten life, so skipping it has a cost of its own. A useful question is whether the decision rests on a formal look at strength, nutrition and other illnesses, or only on the birth date.

Tumor biology and other illnesses play a part too. Older women with advanced disease had more other health conditions, yet those conditions were not strongly tied to the treatment they got.⁹ Their tumors, however, were less often responsive to platinum chemotherapy, the main drug type used.¹⁰ A common gene change in this cancer also appears more often in older patients’ tumors.¹¹

The statistics blend robust and very frail older women, and also include women who chose comfort-focused care only, which pulls the averages down. A fit older woman who gets full surgery and chemotherapy likely does better than the group figure suggests, though the studies don’t give her exact odds.

Can Older Women Handle Surgery and Chemotherapy

Often they can. Women 70 and older with advanced ovarian cancer received about 96-100% of planned doses of standard platinum and paclitaxel chemotherapy.¹² They had no more treatment delays or dose cuts than expected.¹³

Debulking surgery is an operation to remove as much visible tumor as possible. With a geriatrics team helping manage care, older women with stage 3C or 4 had as much tumor removed as possible in 97% of cases and all visible tumor in 63%.¹⁴ More doctors now start with chemotherapy and operate afterward, a shift seen at all ages.¹⁵ Chemotherapy first can make the surgery smaller and safer for an older woman.

A geriatric assessment is a structured check of daily function, memory, nutrition, mood and medicines. It can predict who will have severe side effects and how long they will live.¹⁶ A simple vulnerability score of 3 or more flagged older women more likely to stop treatment early, have serious side effects and need hospital stays.¹⁷ In practice it means questions about walking, falls and daily tasks, a brief memory and mood screen, and a review of all medicines and any weight changes. The results can lead to extra support rather than less treatment. It is worth asking whether such an assessment can be done before treatment starts.

Some questions to bring to the oncologist:

Is surgery planned? If not, what specific reason was given, such as extent of spread or health concerns?
Will chemotherapy come first to shrink the tumor, and would surgery follow if it responds?
Can a geriatrician or similar specialist join the team to help manage other health conditions during treatment?
What help is available at home for nausea, tiredness and low blood counts, and whom should we call if something goes wrong?

How Newer Maintenance Drugs Work in Older Women

PARP inhibitors are daily pills, such as olaparib, taken after chemotherapy to keep the cancer from returning. In older women they cut the risk of the cancer growing again by about half compared with placebo, similar to younger women.¹⁸ Older women, though, had a higher risk of severely low platelets, the blood cells that help clotting.¹⁹

In one trial of women with BRCA mutations, older women more often stopped olaparib for side effects and more often developed rare blood cancers.²⁰ A longer overall life with olaparib was seen in younger women but not shown in the small older group.²¹ On the other hand, older women taking olaparib with bevacizumab kept their general quality of life and thinking skills as well as or slightly better than those on placebo.²²

The evidence is mixed: delaying the cancer’s return is not the same as living longer. The higher risk of low platelets and rare blood cancers means the benefit should be weighed against the risks for her specifically. Suitability also depends partly on tumor genetics, so ask whether BRCA or similar testing has been done on the tumor or in blood.

While taking PARP inhibitor pills, regular blood tests check platelets and red blood cells, often every few weeks at the start. Tell the care team about unusual bruising, nosebleeds, bleeding gums, black stools, or new paleness and breathlessness. Tiredness out of proportion to daily activity should be reported rather than put down to age. A lower dose or a short pause often controls side effects, so a woman does not necessarily have to stop the pills.

Immunotherapy data are very early. In one very small preliminary report, older women responded better to immune checkpoint drugs than younger women.²³ With only 15 patients, it is not something to plan treatment around.

Chances of Living 10 Years or More

A minority of women do become long-term survivors. About 17% of women with stage 3 or 4 epithelial ovarian cancer lived more than 10 years.²⁴ Among women under 50 with advanced disease, 26% passed 10 years.²⁵ Most women over 75 with advanced disease lived under two years, though 6% lived beyond 10.²⁶

Each year a woman lives, her chance of reaching the next milestone is worked out again among those still alive. The first months carry the highest risk, because treatment is under way and early recurrences or complications are most likely then.

Among stage 4 women already alive at 5 years, about 26% of those under 65 and 29% of those 65 and older were still alive 5 years later.²⁷ Once a woman reaches 5 years, age no longer clearly predicts reaching 10. By 10 years, the gap in excess deaths between older and younger women also narrows.²⁸ Long-term survivors tend to be women who had all visible tumor removed and whose cancer responded to platinum chemotherapy.

Quality of Life and Symptom Care by Age

Older ovarian cancer survivors report clearly weaker physical functioning than younger survivors.²⁹ Yet older survivors who had chemotherapy reported better physical function and less pain and sleeplessness, while younger survivors reported the opposite.³⁰ Fear of losing independence shouldn’t by itself rule out chemotherapy for an older woman.

Near the end of life, about 6 in 10 women with ovarian cancer needed invasive procedures, such as drains or tubes, to manage symptoms.³¹ Women receiving those procedures were on average about 9 years younger.³² Each extra decade of age lowered the odds of getting them.³³ Families of older women can ask whether a bowel or fluid drain is an option for comfort.

Fluid building up in the belly can cause bloating, pressure and trouble breathing, and it can be drained through a thin tube to bring relief. A bowel blockage, which causes vomiting and cramping pain, may be treated with a tube to relieve pressure or with surgery in selected women. Palliative care teams focus on comfort and can work alongside cancer treatment from early on, not only in the final weeks. Families can ask for a referral at any stage; it does not mean stopping treatment.

Clinical Trials for Older Women

About 61% of new ovarian cancer cases occur in women over 65.³⁴ Yet enrollment of older women in clinical trials has been very low.³⁵ Treatment evidence for older women is thinner as a result. It is worth asking the oncologist whether a suitable trial exists, regardless of age.

ClinicalTrials.gov is a public registry where you can search by condition, such as ovarian cancer, and by your location. Read the eligibility criteria carefully, since some trials set upper age limits or require certain levels of fitness and organ function. Ask about the practical load, including how far you must travel, how many extra visits are needed and which costs are covered. Your oncologist can help judge whether a trial offers a reasonable chance of benefit compared with standard treatment.